In addition, we compared baseline serum CHIT1 activity and YKL-40 concentrations in IPF and control subjects and explored the possible relationship of serum CHIT1 and YKL-40 to serial clinical measures in a cohort of patients with IPF starting antifibrotic therapy. The gene discussed is CHIT1; the disease is idiopathic pulmonary fibrosis.